Bioaerosol components such as lipopolysaccharide (LPS) are potent inducers of the inflammatory response and associated with diseases including chronic obstructive pulmonary disease (COPD). To assess the health risks associated with bioaerosol emissions, appropriate technology is required to investigate exposure-response relationships. Cell-based biosensors have been recognized as potential leaders in the next generation of functional biosensing as they provide rapid and useful information on physiological responses to a variety of bioactive analytes. Alveolar macrophages (AM) are the first line of defence against airborne environmental microbes. Recently, we described a novel, continuously growing, non-transformed, model of lung AMs (MPI cells), a first in the field (Fejer et al, 2013). This robust system provides an excellent new model for AMs without restricted availability.